Skip to content

Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa

A Study of the Effects of Antiretroviral Therapy on Rates and Transmission of Tuberculosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00346476
Enrollment
1250
Registered
2006-06-30
Start date
2006-04-30
Completion date
2010-12-31
Last updated
2011-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Tuberculosis

Keywords

TB, Transmission, Genetic Diversity, Genetic Testing, RFLP

Brief summary

The purpose of this study is to determine the number of people infected with tuberculosis (TB) in the Masiphumelele Township of Cape Town, South Africa, a community with high rates of TB and HIV. This study will also examine the genetics of TB and the relationships among active TB infection, new HIV infections, and HIV disease progression.

Detailed description

TB is the most common opportunistic infection and the single most common cause of death in HIV infected people in Africa today. Latent TB infection has been known to revert to active TB following new infection in HIV infected people; also, TB has been shown to accelerate the progression of HIV disease. These epidemiologic relationships between TB and HIV and the high prevalence of these diseases in sub-Saharan Africa make studying TB and HIV infected populations in this region of the world important. The Masiphumelele Township of Cape Town, South Africa, with its high rates of TB and HIV, is representative of many poor communities in Africa. The purpose of this study is to observe people from the Masiphumelele Township over a 5-year period to assess the prevalence of TB and HIV infections in a random sample of people and the clinical and genetic characteristics of active TB infection. This study has two parts: a random cross-sectional survey and a clinical and genetic assessment of TB patients. Participants in the random survey will only be involved with the study for a maximum of 2 days. The purpose of the first part of the study is to compare the prevalence of active TB and the prevalence of HIV infection in a random sample of people from the Masiphumelele Township. In this part of the study, children and adults will be randomly selected from the township population to determine the prevalence of active TB and the prevalence of HIV infection in this group of people. Fieldworkers will identify eligible participants in the township and will ask them to visit the clinic that day or the next. At the clinic, participants will be asked to complete a demographics and TB history questionnaire and provide a saliva sample for anonymous HIV testing. A sputum sample will be collected from each participant with a nebulizer; each participant will also be given a sputum sample bottle and will be asked to collect an early morning sputum sample on the next day that will be returned to the clinic. The second part of the study will enroll TB patients. Participants in this part of this study will be followed for the course of their TB treatment for at least 6 months. The purpose of the second part of the study is to assess changes through time of the clustering and transmission of TB among HIV infected and uninfected people in the Masiphumelele Township. This assessment will include examining the diversity of TB strains in this population and determining the relationship between recurrent cases of TB and HIV infection. All sputum samples indicating TB infections that were previously collected from participants will undergo genetic testing by restriction fragment length polymorphism (RFLP) analysis. Participants will be asked to complete a demographics and TB history questionnaire and provide a saliva sample for anonymous HIV testing. Participants will also be interviewed about treatment they have received for TB, their responses to this treatment, and whether they are currently on highly active antiretroviral therapy (HAART) for the treatment of HIV infection. Participants who are found to be infected with TB during the first part of the study will be offered TB treatment through the clinic and will be invited to participate in the second part of this study. Participants who are found to be infected with HIV during the study will be referred to further treatment and evaluation.

Interventions

None listed

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH
Comprehensive International Program of Research on AIDS
CollaboratorOTHER
CIPRA SA
Lead SponsorNETWORK

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

for All Participants: * Willing to comply with study requirements * Parent or guardian willing to provide informed consent, if applicable Inclusion Criteria for Participants in First Part of the Study: * Live in Masiphumelele Township, Cape Town, South Africa for at least 1 week Inclusion Criteria for Participants in Second Part of the Study: * Live in Masiphumelele Township, Cape Town, South Africa * Registered TB patient at the study site

Exclusion criteria

for All Participants: * Currently incarcerated

Design outcomes

Primary

MeasureTime frame
Number of Participants With Microbiologically Confirmed Tuberculosis InfectionAt Year 5
Number of Participants With HIV InfectionAt Year 5

Secondary

MeasureTime frame
Changes in Clustering and Transmission of TB Among HIV Infected and Uninfected ParticipantsYear 1 to Year 5
Changes in the Clustering and Transmission of TB Among HIV Infected and Uninfected Participants After the Introduction of HAARTYear 1 to Year 5
Diversity of TB Strains Among HIV Infected Participants Receiving HAART, HIV Infected Participants Not Receiving HAART, and HIV Uninfected ParticipantsYear 1 to Year 5
Number of Recurrent Cases of TB Attributable to Endogenous Reactivation Versus Exogenous Re-infection in Both HIV Infected and Uninfected ParticipantsAt Year 5

Countries

South Africa

Participant flow

Participants by arm

ArmCount
Participants
Individuals in the Masiphumelele Township of Cape Town, South Africa, who have been potentially exposed to TB and/or HIV
1,250
Total1,250

Baseline characteristics

CharacteristicParticipants
Age, Categorical
<=18 years
55 Participants
Age, Categorical
>=65 years
10 Participants
Age, Categorical
Between 18 and 65 years
1185 Participants
Age Continuous28.9 years
STANDARD_DEVIATION 9.5
Region of Enrollment
South Africa
1250 participants
Sex: Female, Male
Female
602 Participants
Sex: Female, Male
Male
648 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 1,250
serious
Total, serious adverse events
0 / 1,250

Outcome results

Primary

Number of Participants With HIV Infection

Time frame: At Year 5

ArmMeasureValue (NUMBER)
ParticipantsNumber of Participants With HIV Infection306 participants
Primary

Number of Participants With Microbiologically Confirmed Tuberculosis Infection

Time frame: At Year 5

ArmMeasureValue (NUMBER)
ParticipantsNumber of Participants With Microbiologically Confirmed Tuberculosis Infection20 participants
Secondary

Changes in Clustering and Transmission of TB Among HIV Infected and Uninfected Participants

Time frame: Year 1 to Year 5

Secondary

Changes in the Clustering and Transmission of TB Among HIV Infected and Uninfected Participants After the Introduction of HAART

Time frame: Year 1 to Year 5

Secondary

Diversity of TB Strains Among HIV Infected Participants Receiving HAART, HIV Infected Participants Not Receiving HAART, and HIV Uninfected Participants

Time frame: Year 1 to Year 5

Secondary

Number of Recurrent Cases of TB Attributable to Endogenous Reactivation Versus Exogenous Re-infection in Both HIV Infected and Uninfected Participants

Time frame: At Year 5

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026